Article Text

Download PDFPDF
IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still’s disease
  1. L Naumann1,
  2. E Feist1,
  3. A Natusch2,
  4. S Langen2,
  5. A Krause2,
  6. F Buttgereit1,
  7. G-R Burmester1
  1. 1
    Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany
  2. 2
    Immanuel-Krankenhaus, Rheumaklinik Berlin-Buch und Berlin-Wannsee, Berlin, Germany
  1. Correspondence to Dr L Naumann, Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Campus Mitte, Charitéplatz 1, 10117 Berlin, Germany; lydia.naumann{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

New therapeutic strategies are required in the management of adult-onset Still’s disease (AOSD) refractory to glucocorticoids, disease-modifying antirheumatic drugs (DMARDs) or anti-tumour necrosis factor α antagonists (anti-TNFs). It has been suggested that interleukin 1 (IL1) plays a key role in the maintenance of the chronic inflammatory diseases, providing a rationale for an IL1-blocking therapy.1 2 Anakinra, an IL1 receptor antagonist (IL1-RA) approved for the treatment of rheumatoid arthritis,3 has shown promising results in small cohorts of patients with AOSD.4 5 6 7 8 However, it is unclear whether these effects can be sustained over a long treatment period. We report rapid and long-lasting responses to anakinra in eight patients with AOSD refractory to glucocorticoids, DMARDs and/or anti-TNFs.

From December 2004, eight consecutive patients with refractory adult-onset …

View Full Text


  • Competing interests None.

  • Provenance and Peer review Not commissioned; externally peer reviewed.